Implant revolutionising epilepsy seizure detection and forecasting

MedTech News: An Australian medtech company signed a strategic collaboration to accelerate ultra-long term EEG monitoring so people who suffer from seizures have an advanced digital therapeutics product to detect and forecast their seizures.

Epiminder is evaluating its Minder ultra-long term EEG implant at St Vincent’s Hospital in Melbourne. These ultra-long term EEG recordings produce enormous data sets and require advanced algorithms and data curation to generate new insights into patient seizure patterns.

Leveraging Seer Medical’s advanced capabilities in cloud and app-based platforms to detect, report and forecast seizures and abnormal brain activity, will enable, for the first time, specialists in this field to better understand individual patients’ circumstances and medication.

University of Melbourne Professor Mark Cook, Chair of Medicine at St Vincent’s Hospital Melbourne, said “Many people with epilepsy do not achieve adequate control of their seizures. Many of these people live in persistent anxiety and everyday tasks like driving or cooking can become life-threatening. Seer Medical and Epiminder have very complementary technologies that, together, have the potential to dramatically improve epilepsy care.”

You may also like Data is the biggest challenge, and opportunity, for MedTech

Rohan Hoare, CEO of Epiminder said, “This agreement between Seer Medical and Epiminder is poised to accelerate the clinical insight of Minder EEG recordings and potentially add substantial value to our product offering.”

Dean Freestone, CEO of Seer Medical said “Bringing together the Minder EEG monitor and the Seer Cloud technology, patients will be able to gauge the likelihood of a seizure occurring via an app, bringing back control into people’s lives.”

Epilepsy affects 65 million people globally. Refractory epilepsy affects 30% to 40% of these patients, who cannot be adequately managed by drug therapy to remain seizure free.

Epiminder was launched in June 2018 to commercialise intellectual property created by a research team led by Professor Mark Cook, Neurologist at St Vincent’s Hospital, Melbourne and Chair of Medicine at the University of Melbourne; and Associate Professor Chris Williams from Bionics Institute.